Modopar 125 (Benserazide Hydrochloride, Levodopa)

Levodopa, the active ingredient in Modopar 125, is a Antiparkinson agent presented as a Levodopa 125 mg / Benserazide 31.25 mg tablet for oral use. It treats Parkinson's disease and Parkinsonian syndrome in patients.

GNH USA supplies Modopar 125 as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Modopar 125, a combination of levodopa and benserazide, is used in the management of Parkinsonian disorders. - Parkinson's disease: improves motor symptoms and functional ability. - Parkinsonian syndrome: reduces rigidity, tremor and bradykinesia.

Levodopa/benserazide therapy may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: feeling of stomach upset, often occurring early in treatment. - Vomiting: expulsion of stomach contents, may accompany nausea. - Dizziness: light‑headed sensation, especially when standing. - Orthostatic hypotension: drop in blood pressure upon standing, causing faintness.

Serious or Rare Side Effects: - Dyskinesia: involuntary, erratic movements that can affect limbs and face. - Psychiatric disturbances: hallucinations, confusion or mood changes. - Severe hypotension: marked blood pressure fall leading to syncope. - Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever and muscle rigidity.

When prescribing Modopar 125, clinicians should observe several precautionary measures to ensure safe use. - Monitor blood pressure: check for orthostatic changes, especially at treatment initiation. - Assess for dyskinesia: adjust dose if involuntary movements develop. - Avoid use in narrow‑angle glaucoma: may exacerbate intra‑ocular pressure. - Use with caution in hepatic impairment: impaired metabolism may increase exposure. - Store at ambient temperature: keep in the original pack, protect from moisture.

Levodopa/benserazide can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis when combined. - Antipsychotics (e.g., haloperidol): may block dopamine receptors and reduce therapeutic effect. - Antihypertensive agents: additive hypotensive effect leading to excessive blood pressure drop.

Moderate Interactions (Monitor Closely): - SSRIs or SNRIs: potential for serotonin syndrome when used together. - Iron or calcium supplements: may bind levodopa in the gut and reduce absorption. - High‑protein meals: compete with levodopa transport, decreasing its bioavailability.